This data is for laboratory research purposes only. Not for human or animal consumption.
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily for obesity management and type 2 diabetes. This case report documents a rare but clinically significant adverse effect: reversible central respiratory depression leading to nocturnal hypercapnia.
Mechanism of Action
Semaglutide activates GLP-1 receptors in the hypothalamus and brainstem to enhance satiety signaling and glucose homeostasis. However, GLP-1 receptor expression in respiratory control centers (particularly the nucleus tractus solitarius and dorsal motor nucleus of the vagus) may modulate ventilatory drive. Excessive GLP-1 receptor agonism can suppress central ventilatory response to CO₂, impairing the brain's chemoreceptor-mediated breathing regulation independent of airway obstruction or sleep-disordered breathing pathology.
Observed Laboratory Results
- Respiratory acidosis (pH 7.33; normal 7.35–7.45) with elevated PaCO₂ 56 mmHg (normal 35–45 mmHg) four weeks post-dose escalation to 1 mg/week
- Normal alveolar-arterial (A-a) gradient and Apnea-Hypopnea Index <5 events/hour, excluding conventional sleep apnea; transcutaneous capnography confirmed sustained nocturnal hypercapnia without apneic episodes
- Complete resolution of respiratory acidosis (pH 7.38, PaCO₂ 44 mmHg) within 3 weeks of semaglutide discontinuation plus temporary noninvasive ventilation
Clinical Significance
This case establishes a previously unreported association between GLP-1 receptor agonist dose escalation and central ventilatory drive impairment. Clinicians should monitor for unexplained hypercapnia, excessive daytime sleepiness, and morning headaches in patients receiving semaglutide, particularly after dose increases, and consider this diagnosis in cases where conventional sleep-disordered breathing evaluations are negative.